The fees and costs outlined in the $26 billion opioid deal with Johnson & Johnson’s Janssen Pharmaceuticals and three distributors are a mix of common benefit fees, contingency fees and payments to the states for outside counsel. One law professor said, “it’s not like the lawyers are going to be impoverished.”
Leave a Reply